Madrigal Pharmaceuticals, Inc.
NASDAQ•MDGL
CEO: Mr. William J. Sibold
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2007-02-06
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Contact Information
Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, PA, 19428, United States
267-824-2827
Market Cap
$10.17B
P/E (TTM)
-34.5
17.2
Dividend Yield
--
52W High
$615.00
52W Low
$265.00
52W Range
Rank57Top 83.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$321.08M+0.00%
4-Quarter Trend
EPS
-$2.57+0.00%
4-Quarter Trend
FCF
-$133.07M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Rezdiffra Product Revenue Surge Net product revenue reached $958.4M in 2025, a massive increase from $180.1M in 2024, driven by strong commercial execution.
Global Commercial Launch Progress Launched Rezdiffra in US (April 2024) and Germany (September 2025); secured US patent protection for dosing until February 2045.
Pipeline Expansion Secured Acquired exclusive global licenses for MGL-2086 (GLP-1) and ervogastat (DGAT-2) in 2025, bolstering the focused MASH pipeline.
Strong Cash Position Maintained Cash, cash equivalents, and marketable securities totaled $988.6M as of December 31, 2025, funding operations past one year.
Risk Factors
Sole Product Dependency Risk Business highly dependent on Rezdiffra success; accelerated approval requires confirmatory data from ongoing post-marketing trials.
Continued Operating Losses Expected Accumulated deficit reached $2.090B by year-end 2025; expects to incur additional operating losses while commercializing Rezdiffra.
Competitive Landscape Intensifying Over 140 drugs in development for MASH; competition includes Novo Nordisk's semaglutide, which was approved in the US.
Regulatory Approval Contingency Full US approval contingent on positive outcomes from MAESTRO-NASH OUTCOMES trial, with expected readout in 2027.
Outlook
Maximizing Rezdiffra Commercial Value Targeting quarterly sales annualizing greater than $1.0B by December 31, 2025, leveraging broad first-line payer access.
Expanding Rezdiffra Indication Potential Expect 2027 data readout from OUTCOMES trial to support full approval and potential F4c cirrhosis indication expansion.
Advancing Next-Generation Pipeline Plan to initiate MGL-2086 Phase 1 study in Q2 2026; IND-enabling activities for six siRNA candidates expected to begin in 2026.
Liquidity Funding Strategy Available cash sufficient to fund operations past one year; future needs may require equity/debt financing or strategic partnerships.
Peer Comparison
Revenue (TTM)
$11.24B
$4.27B
$3.22B
Gross Margin (Latest Quarter)
97.9%
96.1%
95.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VRNA | $72.68B | -145.1 | -30.0% | 42.7% |
| MRNA | $21.30B | -7.5 | -30.1% | 15.5% |
| ROIV | $20.25B | -24.4 | -18.3% | 4.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
32.8%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data